



**HAL**  
open science

# Cellular Inhibitor of Apoptosis Protein-1 (cIAP1) Can Regulate E2F1 Transcription Factor-mediated Control of Cyclin Transcription

Jessy Cartier, Jean Berthelet, Arthur Marivin, Simon Gemble, Valérie Edmond, Stéphanie Plenchette, Brice Lagrange, Arlette Hammann, Alban Dupoux, Laurent Delva, et al.

► **To cite this version:**

Jessy Cartier, Jean Berthelet, Arthur Marivin, Simon Gemble, Valérie Edmond, et al.. Cellular Inhibitor of Apoptosis Protein-1 (cIAP1) Can Regulate E2F1 Transcription Factor-mediated Control of Cyclin Transcription. *Journal of Biological Chemistry*, 2011, 286 (30), pp.26406-26417. 10.1074/jbc.M110.191239 . inserm-02337357

**HAL Id: inserm-02337357**

**<https://inserm.hal.science/inserm-02337357v1>**

Submitted on 29 Oct 2019

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

# Cellular Inhibitor of Apoptosis Protein-1 (cIAP1) Can Regulate E2F1 Transcription Factor-mediated Control of Cyclin Transcription<sup>\*[5]</sup>

Received for publication, October 4, 2010, and in revised form, June 6, 2011. Published, JBC Papers in Press, June 8, 2011, DOI 10.1074/jbc.M110.191239

Jessy Cartier<sup>‡§1</sup>, Jean Berthelet<sup>‡§1</sup>, Arthur Marivin<sup>‡§</sup>, Simon Gemble<sup>‡§</sup>, Valérie Edmond<sup>¶||</sup>, Stéphanie Plenchette<sup>‡§</sup>, Brice Lagrange<sup>‡§</sup>, Arlette Hammann<sup>‡§</sup>, Alban Dupoux<sup>‡§</sup>, Laurent Delva<sup>‡§</sup>, Béatrice Eymin<sup>¶||</sup>, Eric Solary<sup>‡§\*\*\*</sup>, and Laurence Dubrez<sup>‡§2</sup>

From the <sup>‡</sup>Institut National de la Santé et de la Recherche Médicale (Inserm) UMR866, Dijon, F-21079, France, the <sup>§</sup>Faculty of Medicine, University of Burgundy, Institut Fédératif de Recherche (IFR) 100, Dijon, F-21079, France, the <sup>¶</sup>Inserm U823, Equipe Bases Moléculaires de la Progression des Cancers du Poumon, Institut Albert Bonniot, Grenoble F-38042, France, the <sup>||</sup>Université Joseph Fourier, Grenoble, F-38041, France, and <sup>\*\*\*</sup>Inserm UMR1009, Institut Gustave Roussy, Villejuif, F-94805, France

The inhibitor of apoptosis protein cIAP1 (cellular inhibitor of apoptosis protein-1) is a potent regulator of the tumor necrosis factor (TNF) receptor family and NF- $\kappa$ B signaling pathways in the cytoplasm. However, in some primary cells and tumor cell lines, cIAP1 is expressed in the nucleus, and its nuclear function remains poorly understood. Here, we show that the N-terminal part of cIAP1 directly interacts with the DNA binding domain of the E2F1 transcription factor. cIAP1 dramatically increases the transcriptional activity of E2F1 on synthetic and *CCNE* promoters. This function is not conserved for cIAP2 and XIAP, which are cytoplasmic proteins. Chromatin immunoprecipitation experiments demonstrate that cIAP1 is recruited on E2F binding sites of the *CCNE* and *CCNA* promoters in a cell cycle- and differentiation-dependent manner. cIAP1 silencing inhibits E2F1 DNA binding and E2F1-mediated transcriptional activation of the *CCNE* gene. In cells that express a nuclear cIAP1 such as HeLa, THP1 cells and primary human mammary epithelial cells, down-regulation of cIAP1 inhibits cyclin E and A expression and cell proliferation. We conclude that one of the functions of cIAP1 when localized in the nucleus is to regulate E2F1 transcriptional activity.

Cellular inhibitor of apoptosis protein-1 (cIAP1,<sup>3</sup> also named BIRC2, HIAP2) belongs to the IAP family of proteins that all

contain at least one copy of the conserved BIR (baculoviral IAP repeat) domain (1, 2). cIAP1 also contains a central CARD (caspase-activating recruitment domain) and a C-terminal RING (really interesting new gene) domain, the latter conferring to the protein an E3 ubiquitin ligase activity. cIAP1 is an important regulator of the signaling pathways activated by the tumor necrosis factor (TNF) receptor superfamily members and modulates nuclear factor- $\kappa$ B (NF- $\kappa$ B) activation (3–6). cIAP1 has the capacity to bind and ubiquitylate several signaling intermediates involved in these pathways, including TRAF2 (TNF receptor-associated factor 2) (1, 5–8), NIK (NF- $\kappa$ B-inducing kinase) (9), ASK1 (apoptosis signal-regulating kinase 1) (10), NEMO (NF- $\kappa$ B essential modulator) (11), and RIP1 (12, 13).

A range of evidence suggests that cIAP1 plays a role in mammalian cancers. cIAP1-encoding *Birc2* is a target gene within a chromosome 11q21 amplicon found in cervical, oral, head and neck, lung, esophageal, and hepato-cellular carcinomas (14–18). Independently of the presence of this amplicon, cIAP1 is highly expressed in cancer samples from several origins (18–22). The oncogenic properties of cIAP1 have been demonstrated in *p53*<sup>-/-</sup>, c-Myc-expressing mouse hepatocarcinoma cells (18), in *p53*<sup>+/-</sup> mouse osteosarcoma (23), and in *p53*<sup>-/-</sup> mouse mammary carcinoma (24). We (6, 25, 26) and others (27–29) have shown that cIAP1 was expressed mainly in the nucleus of undifferentiated, proliferating cells and was excluded upon cell differentiation (25) or apoptosis induction (27). cIAP1 is also detected in the nucleus of primary human tumor cells (15, 16, 28, 30). In head and neck squamous cell carcinomas (HNSCCs), the nuclear expression of cIAP1 has been associated with lymph node metastasis and advanced disease stages (16, 30), suggesting that the nuclear function of cIAP1 could account for its oncogenic properties. The nuclear function of cIAP1 remains misunderstood. In the present study, we demonstrate that cIAP1 directly interacts with the transcription factor E2F1 and stimulates its transcriptional activity when recruited on *CCNE* and *CCNA* gene promoters. These genes are important regulators of cell cycle progression and cell proliferation (31, 32), promoting the transition from G<sub>1</sub> to S phase of the cell cycle (31, 32). E2F1 transcriptional activity is regulated by its dimerization with the co-activator DP1

\* This work was supported by grants from the Ligue Nationale Contre le Cancer (équipe labellisée, E5) and the Comité de Côte d'Or, Nièvre, Saône et Loire and Yonne of the Ligue contre le Cancer (to L. D.), the Association pour la Recherche sur le Cancer (ARC, to L. D.), the association "Cent pour Sang la Vie", the Association Nationale de la Recherche and the National Institute of Cancer, and fellowships from the "Ministère de l'Enseignement Supérieur et de la Recherche" of France (to J. C., A. D., J. B., A. M., B. L. and S. P.) and ARC (to J. C.).

[5] The on-line version of this article (available at <http://www.jbc.org>) contains supplemental Figs. S1–S6.

<sup>1</sup> Both authors contributed equally to this work.

<sup>2</sup> To whom correspondence should be addressed: Inserm UMR866, Faculty of Medicine, 7 boulevard Jeanne d'Arc, 21079 Dijon Cedex, France. Tel.: 33-380-393-356; Fax: 33-380-393-434; E-mail: ldubrez@u-bourgogne.fr.

<sup>3</sup> The abbreviations used are: cIAP1, cellular inhibitor of apoptosis protein-1; CARD, caspase-activating recruitment domain; MEF, mouse embryonic fibroblasts; RING, really interesting new gene; BIR, baculoviral IAP repeat; UBA, ubiquitin-associated domain; DP1, dimerization partner 1; HMEC, human mammary epithelial cells; Rb, retinoblastoma protein.

(Dimerization Partner 1), which favors DNA binding and the recruitment of a number of other proteins (33, 34) that behave as activators or repressors (33–35). One of the functions of cIAP1 in the nucleus appears to be part of the molecular machinery that regulates the transcriptional activity of E2F1 on *CCNE* and *CCNA* promoters.

## EXPERIMENTAL PROCEDURES

**Cell Culture, Chemicals, and Treatments**—Human mammary epithelial cells (HMEC) were purchased from Invitrogen (Cergy Pontoise, France) and grown into HMEC ready medium (Invitrogen). Mouse embryonic fibroblasts (MEF) were provided by J. Silke (Melbourne, Australia). THP1, HT-29, U-2 OS, and CaSki cell lines were grown into RPMI 1640 and MEF and HeLa cells in DMEM medium (Lonza, Verviers, Belgium) supplemented with 10% fetal bovine serum (Lonza). Cells were synchronized using 2 mM thymidine (Sigma-Aldrich) double block. Human CD34<sup>+</sup> progenitor cells were prepared from human umbilical cord blood (Etablissement Français du Sang) as previously described (36), cultured over 7 days in StemSpan<sup>TM</sup> H3000, supplemented with 100 ng/ml rhFlt-3 ligand, 100 ng/ml rhSCF, 20 ng/ml rhIL-3, and 20 ng/ml rhIL-6 (StemCell Technologies, Vancouver, BC, Canada), and then differentiated for 2 weeks into CD14<sup>+</sup> monocytic cells by exposure to 25 ng/ml M-CSF (StemCell Technologies) before ChIP experiments. The pan-caspase inhibitor zVAD-fmk was from Sigma-Aldrich.

**Transfections, Plasmid Constructs, and siRNA**—THP-1 cells were nucleoporated using the AMAXA nucleofactor kit V (Amaxa Biosystems, Lonza). Stable THP1 clones expressing cIAP1 antisense were enriched by a 10-day geneticin selection (0.5 mg/ml). Cells were transfected using JET PEI (Polyplus transfection, Ozyme, Saint-Quentin-en-Yvelines, France), Lipofectamine 2000 (Invitrogen) or Interferin (PolyPlus transfection, Ozyme) transfection reagent. DNA constructs used were pcDNA, pcDNA-cIAP1, pcDNA-cIAP1 in antisense orientation (AS), pcDNA-cIAP2, pcDNA-XIAP, pEGFP, pEGFP-cIAP1, pCI, pCI-cIAP1, pCI-cIAP1-H588A, pGL3, pGL-5x E2F-BS, pGL-human *CCNA* promoter, pGL-human *CCNE* promoter wt and mutated in E2F binding sites, pCMV-E2F1, pcDNA-E2F2 and E2F-3a. pGEX-based constructs (cIAP1, cIAP1-BIR1-3 (amino acid 1–483), cIAP1-CARD-RING (amino acid 452–618), E2F1, E2F1 amino acid 284–437, E2F1 amino acid 89–191, E2F1 amino acid 41–108, E2F1 amino acid 41–127) were obtained by cloning PCR-generated DNA sequence into pGEX 4T1 (GE Healthcare, Chalfont St. Giles, UK). FLAG-cIAP1 constructs were generated by cloning cIAP1-full length, cIAP1-BIR1-3, cIAP1-CARD-RING in a FLAG-pCR3 vector (Invitrogen). The cIAP1 L47A mutant was generated by site-directed mutagenesis. RNA oligonucleotides used were cIAP1, E2F1, and control siRNA sequence designed and purchased from Qiagen.

**Cell Extracts, Immunoprecipitation, and Western Blot Analysis**—Cell lysates and immunoblot analysis were performed as described (6). Nuclear- and cytoplasm-enriched fractions were obtained as described (25).

Primary antibodies used were rabbit anti-human cIAP1 (R&D Systems, Lille, France), GFP (BD Biosciences, Le Pont de

Claix, France), TRAF2 (Stressgen), PARP, E2F1, E2F2 and E2F3 (Santa Cruz Biotechnology, Santa Cruz, CA), goat anti-human cIAP1, XIAP (R&D systems), GST (Rockland, PA), mouse anti-human cIAP2 (R&D systems), cyclin A, cyclin E (BD Biosciences), cyclin B, Rb (Cell signaling Technology, Danvers, MA), and HSC70 (Santa Cruz Biotechnology) monoclonal antibodies. Secondary antibodies included goat HRP-conjugated anti-mouse, anti-rabbit, anti-rat, or rabbit anti-goat immunoglobulins (Jackson ImmunoResearch Laboratories, Bar Harbor, ME).

For immunoprecipitation, cells were lysed in a buffer containing 50 mM Tris-HCl, pH 7.4; 150 mM NaCl; 20 mM EDTA; 0.5% Nonidet P-40; 1 mM DTT, and protease inhibitors and incubated overnight at 4 °C under shaking in the presence of anti-E2F1 Ab (C-20, Santa Cruz Biotechnology) or anti-cIAP1 Ab (R&D Systems) coupled to Sepharose G-protein beads (Amersham Biosciences, GE Healthcare) or ANTI-FLAG<sup>®</sup> M2 Affinity Agarose Gel (Sigma-Aldrich). Beads were washed and resuspended in Laemmli 1× buffer before immunoblot analysis. The co-precipitation experiments were performed in HeLa cells transfected with FLAG constructs and pCMV-E2F1.

**Antibody Array**—HeLa cells were transfected with pEGFP-NES<sup>\*</sup>-cIAP1 (25). The cell lysate was deposited onto a Cell Cycle antibodyArray<sup>TM</sup> (Hypromatrix, Worcester, MA) containing 60 specific antibodies against cell cycle-related proteins following the manufacturer's instructions and immunoblotted with anti-GFP biotin (USBiological, Swampscott, MA) and biotin-HRP (Invitrogen) antibodies.

**GST-Pull-down Assay**—GST fusion proteins were produced in *Escherichia coli*, immobilized on glutathione-Sepharose (Amersham Biosciences), and incubated with either HeLa cell lysates or *in vitro* translated [<sup>35</sup>S]methionine-labeled cIAP1 protein or recombinant human E2F1 protein (Protein One, Bethesda, MD). The bound proteins to GST-cIAP1 constructs were revealed by immunoblotting. The bound proteins to GST-E2F1 constructs were revealed by immunoblotting or by 10% SDS-PAGE and autoradiography.

**Gene Reporter Assay**—Cells were transfected with 500 ng of pGL-based constructs, 50 ng of pCMV β-gal reporter vector, and 500 ng of IAP constructs, and/or 100 ng of E2F constructs. Cells were harvested 48 h after and analyzed for luciferase activity using the luciferase assay reagent (Promega, Madison, WI) and a luminometer (Lumat LB9507, Berthold, Thoiry, France). Results were normalized to the β-galactosidase activity using the β-Galactosidase Enzyme Assay System kit (Promega).

**RNA Purification, Reverse Transcription, PCR, and Real-time PCR (qPCR)**—Total RNA was isolated using the Nucleospin RNA II kit (Macherey-Nagel, Hoerd, France) or TRIzol Reagent (Invitrogen), reverse transcribed by MMLV reverse transcriptase with oligo(dT) primers (Promega). Specific cDNAs were amplified on an iCYCLER thermocycler (Bio-Rad) or a 7500 FAST thermocycler (Applied Biosystems, Foster City, CA) using the SyBr Green detection protocol. Results were compared with the cyclophilin or HPRT DNA amplification. Primers used for the specific amplification are available upon request. For RT-PCR, the one-step RT-PCR kit (Qiagen) and the iCYCLER thermocycler (Bio-Rad) were used.

**Chromatin Immunoprecipitation Assay**—Cells were formaldehyde cross-linked, and DNA was isolated and sonicated.

## cIAP1 Is a Transcriptional Co-regulator of E2F1

Samples were immunoprecipitated using rabbit or goat anti-human cIAP1 (R&D systems), rabbit anti-human E2F1 (C-20, Santa Cruz Biotechnology), anti-AcH3, or DiMeH3K9 pAbs (Upstate, Millipore, Saint-Quentin-en-Yvelines, France), washed, and reverse cross-linked using the chromatin immunoprecipitation kit EZ ChIP from Upstate (Millipore). For the sequential ChIP experiment, samples were first immunoprecipitated with anti-E2F1 pAb. The antibody-bound protein/DNA complexes were eluted using elution buffer (1% SDS, 0.1 M NaHCO<sub>3</sub>), and a second ChIP was performed using the anti-cIAP1 pAb. PCR and real-time PCR were performed as described above using primers flanking the E2F binding site in *CCNE* and *CCNA* promoters.

**Cell Cycle Analysis**—Cells were incubated for 30 min in the presence of 3 mM BrdU (Sigma Aldrich). Cells were fixed at 4 °C and resuspended in 30 mM HCl and 0.5 mg/ml pepsin for 30 min, then in 2 M HCl over 15 min, stained with primary anti-BrdU Ab, and with secondary anti-mouse Alexa Fluor 488 Ab (Molecular Probes, Invitrogen) and propidium iodide (PI, 10 μg/μl). Cell cycle repartition was assessed by LSRII flow cytometry using FlowJo® Softwares (Tree Star, Inc. Ashland, OR).

**Proliferation Analysis**—We used CellTrace™ CFSE Cell Proliferation kit (for HeLa Cells) or Click-iT™ EdU Cell Proliferation Assay (for HMEC and MEF) (Molecular Probes, Invitrogen) to measure cell proliferation using a LSRII flow cytometer (BD Biosciences) according to the manufacturer's instructions. The index of proliferation was measured using ModFIT Software (Verity Software House Topsham, ME). THP1 cells were plated at the same density and counted each day.

**Statistical Analysis**—Student's *t* test was used for statistical analysis.

## RESULTS


**cIAP1 Interacts with E2F1 through Its BIR Domains**—cIAP1 has been identified in the nucleus of human normal cells, *e.g.* hematopoietic stem cells (25), as well as cancer cells (15, 16, 28, 30). It is also expressed in the nucleus of human colon carcinoma HT-29, human leukemia monocytic THP1 (25, 26), and human epithelial cervix carcinoma HeLa (27) (Fig. 1A) cell lines. To identify nuclear partners of cIAP1, cells were transfected with a GFP-tagged-cIAP1 in which the NES had been mutated to force the nuclear overexpression of the protein (25), and cell lysates were incubated on an antibody array targeting 60 cell cycle-related proteins. Among the 18 detected positive hits, 7 were checked using a higher stringency approach in which GST-cIAP1 is incubated with a cell lysate from untransfected HeLa cells and interactions revealed by immunoblot analysis (Fig. 1B, supplemental Fig. S1A). TRAF2 was used as a positive control (Fig. 1B). Three potential partners were confirmed, namely TTK kinase, Rad52 (supplemental Fig. S1A), and E2F1 transcription factor (Fig. 1B). The GST pull-down experiment also confirmed a negative result of the initial screen, *i.e.* cIAP1 did not interact with the E2F1 repressor retinoblastoma protein (Rb) (Fig. 1B). The reversed GST-pull-down assay demonstrated a binding of endogenous cIAP1 with GST-E2F1 (Fig. 1C). We also detected a very weak binding of cIAP2 and XIAP on GST-E2F1 (Fig. 1C). GST-cIAP1 can inter-

act with purified human E2F1 protein, indicating a direct interaction (Fig. 1D). cIAP1 was co-expressed with E2F1 in the HeLa cell nucleus-enriched fraction whereas cIAP2 and XIAP were detected in the cytoplasm (Fig. 1A). The *in vivo* interaction of E2F1 with cIAP1 was confirmed by co-immunoprecipitation (Fig. 1E).

We then mapped the protein domains required for this interaction by using a co-immunoprecipitation experiment (Fig. 1F) and GST-pull down assay (Fig. 1G and supplemental Fig. S1, B and C). As TRAF2, E2F1 interacted with cIAP1 full-length and with the N-terminal part of the protein that contained BIR 1–3 domains but did not interact with the C-terminal part of cIAP1 that included the CARD and the RING domains (Fig. 1F and supplemental Fig. S1, B and C). Mutation L47A within the BIR1 domain that abolished the cIAP1-TRAF2 interaction (37) did not modify the cIAP1-E2F1 interaction (Fig. 1F). We detected an *in vivo* interaction of cIAP1 with TRAF2 in the nucleus- and in the cytoplasm-enriched fractions by immunoprecipitation (supplemental Fig. S1D). An *in vitro* competition experiment indicated that E2F1 and TRAF2 could compete for cIAP1 binding (supplemental Fig. S1E). GST-pull down assay performed by using *in vitro* translated <sup>35</sup>S-labeled full-length cIAP1 and GST-E2F1 or GST-E2F1 deletion constructs demonstrated that cIAP1 interacted with the E2F1 amino acid sequence 89–191 that overlaps its DNA binding domain (DBD) (Fig. 1G).

**cIAP1 Stimulates E2F1 Transcriptional Activity**—Overexpression or silencing of cIAP1 did not significantly alter the expression level of E2F1 (Fig. 2A). In a luciferase gene reporter assay using a construct containing 5x E2F binding sites upstream of the *LUCIFERASE* gene, overexpressed cIAP1 dramatically enhanced E2F1 transcriptional activity, which was still observed when a mutation was introduced within the RING domain (H588A) of cIAP1 to abrogate its E3 ubiquitin ligase activity (Fig. 2B). We then analyzed the influence of cIAP1 on *CCNE* and *CCNA* promoters, which are two well-identified E2F1 target genes. cIAP1 significantly stimulated *CCNE* gene expression in a dose-dependent manner on its own (Fig. 2C) and substantially enhanced E2F1 activity on *CCNE* (Fig. 2D) and to a lower extent *CCNA* (Fig. 2E) gene promoters. Again, mutation within the RING (H588A) domain or within the BIR1 domain (L47A) that inhibits cIAP1-TRAF2 interaction (Fig. 1F) did not inhibit the capacity of cIAP1 to stimulate E2F1 activity (Fig. 2D and supplemental Fig. S2A). Mutation of E2F binding sites I, II, and III (38) in the *CCNE* promoter of the reporter construct abolished the transcriptional activity of both cIAP1 and E2F1 and prevented the synergistic effect of cIAP1 and E2F1 (Fig. 2F), suggesting that cIAP1 transcriptional effect depended on intact E2F binding sites. These results were confirmed in HT-29 human colon carcinoma cells that harbor a mutated p53 and in U-2 OS osteosarcoma cells that express wild-type p53 (supplemental Fig. S2, B and C). The capacity of cIAP1 to stimulate cyclin E expression was confirmed by RT-qPCR (Fig. 2G, supplemental Fig. S3) and immunoblotting (Fig. 2I) in HeLa (Fig. 2G) and HT-29 (Fig. 2I, supplemental Fig. S3) and silencing of E2F1 decreased the capacity of cIAP1 to stimulate *CCNE* mRNA expression (Fig. 2H).

We then compared the capacity of cIAP1, cIAP2, and XIAP to stimulate E2F1 activity. Overexpression of cIAP1 decreased



**FIGURE 1. clAP1 interacts with the transcription factor E2F1.** *A*, immunoblot analysis of clAP1, clAP2, XIAP, and E2F1 in cytoplasm (C) and nuclear (N)-enriched fractions. PARP is used to check the nuclear fraction. HSC70: loading control. *B–D*, GST pull-down analysis of the interaction of GST-clAP1 (*B*, *D*) or GST-E2F1 (*C*) with indicated proteins from HeLa cell lysate (*B*, *C*) or with purified human E2F1 (*D*). *E*, endogenous E2F1 (*right panel*) or clAP1 (*left panel*) were immunoprecipitated with anti-E2F1, anti-clAP1 or irrelevant rabbit Ig (IgG) in HeLa cells before immunoblot analysis of clAP1 and E2F1. The clAP1 immunoprecipitation (*left*) was performed in a nuclear-enriched fraction. *F*, immunoprecipitation analysis of the interaction of wild type or deletion mutants of clAP1 with E2F1 and TRAF2. FLAG-conjugated proteins and E2F1 were expressed in HeLa cells and co-immunoprecipitated using anti-FLAG M2-agarose beads, then revealed by immunoblotting using an anti-E2F1, anti-TRAF2, or anti-FLAG specific antibody. A schematic representation of E2F1 domains and deletion constructs used is shown (*upper panel*). *G*, GST-pull down analysis of the interaction of *in vitro* translated [<sup>35</sup>S]methionine-labeled clAP1 with indicated GST-E2F1 deletion constructs. The interactions were revealed by autoradiography. E2F1 mutants (*arrows*) were detected after Coomassie Blue staining of the gel (*lower panel*). A schematic representation of E2F1 domains and deletion constructs used is shown (*upper panel*). CBM: cyclin A binding motif; DBD: DNA binding domain; DP: dimerization domain; TAD: C-terminal transactivation domain. Representative experiments are shown.


the expression of clAP2 and XIAP (Fig. 3A), accordingly to the capacity of clAP1 to ubiquitinylate and stimulate the degradation of its close relatives (39). clAP2 and XIAP were much less efficient than clAP1 for stimulating E2F1 activity on synthetic and *CCNE* promoters (Fig. 3, A and B). clAP1 could also stimulate E2F2 and E2F3a, other so-called stimulatory members of the E2F family, although more weakly than E2F1 (Fig. 3C).

**clAP1 Is Recruited on the *CCNE* Promoter**—To explore whether clAP1 could bind to the *CCNE* promoter, we performed chromatin immunoprecipitation (ChIP) using primers that flanked the E2F binding site of the promoter. Primers located inside the *CCNE* gene sequence are used as a negative control. As expected, E2F1 is recruited on the E2F binding site of the *CCNE* promoter (Fig. 4, A and B). clAP1 was detected on the E2F binding site of the *CCNE* promoter in HeLa, U-2 OS,

HT-29, THP1 cell lines and in primary human mammary epithelial cells (HMEC) (Fig. 4, A and C) whereas neither clAP1 nor E2F1 bound the DNA sequence of the *CCNE* gene (Fig. 4, B and C). The same approach was used to demonstrate that clAP1 could also bind the E2F binding site of the *CCNA* promoter in the cell line and in primary human CD34<sup>+</sup> hematopoietic cells (Fig. 4D). ChIP with E2F1 antibody and a Re-ChIP using clAP1 antibody demonstrated that clAP1 and E2F1 were recruited at the same promoter region of the *CCNE* gene (Fig. 4E). These data suggested that clAP1 was a component of the E2F1 transcriptional complex.

**clAP1 Recruitment on Cyclin Gene Promoters Is Cell Cycle-regulated**—To determine whether clAP1-E2F1 interaction could be cell cycle-regulated, HeLa cells were synchronized in early S phase by a thymidine double block ([supplemental Fig. S4](#)).


## clAP1 Is a Transcriptional Co-regulator of E2F1



**FIGURE 2. clAP1 stimulates E2F1 transcriptional activity.** *A*, immunoblot analysis of clAP1 and E2F1 in HeLa cells transfected with clAP1 construct or clAP1 siRNA. HSC70: loading control. *B–F*, gene luciferase experiments performed in HeLa cells transfected with indicated promoter-luciferase reporter plasmids, along with control (Co) or E2F1-encoding vector and/or 500 ng or indicated amount (C) of empty (Co), clAP1 or H588A (*B, D*) encoding constructs. *p(5xE2F BS)*: synthetic promoter containing 5xE2F binding sites (*B*); *p(CCNE)* & wt: wt *CCNE* promoter (*B–D, F*); *p(CCNA)*: *CCNA* promoter (*E*); mutated: E2F binding site-mutated *CCNE* promoter. Luciferase activity was normalized to  $\beta$ -galactosidase activity and expressed as fold induction of promoter stimulated by empty vector alone. Mean  $\pm$  S.D. of one representative experiment. Statistical analysis performed using Student's *t* test. \*\*\*:  $p = 0.0003$ ,  $n = 10$  (*C*); \*:  $p = 0.013$ ,  $n = 3$  (*E*). clAP1 and E2F1 overexpression were checked by immunoblot analysis (*B* right panels, *C* lower panel). *G* and *H*, quantitative RT-PCR analysis of *CCNE* or *birc2* mRNA in HeLa cells transfected with empty or clAP1 encoding vectors and/or E2F1-siRNA (*si-E2F1*). Results are normalized to HPRT mRNA and expressed relative to empty vector (*G*) or expressed as % of *CCNE* mRNA induced by clAP1 in the presence of control siRNA (*H*). Mean  $\pm$  S.D. of one representative experiment. Statistically significant differences (\*\*,  $p = 0.007$ ,  $n = 3$ , Student's *t* test) (*G*). *I*, immunoblot analysis of clAP1 and cyclin E in HT-29 cells transfected with clAP1 construct. The relative expression of cyclin E in clAP1-transfected cells compared with empty vector as evaluated after quantification using ImageJ software was shown on the blot. HSC70: loading control.

The G2/M phase reached 8 h after block release was characterized by a decrease in cyclin E and an increase in cyclin B expression (Fig. 5A). The expression of clAP1 (Fig. 5A), its subcellular localization (not shown), and its interaction with E2F1 (Fig. 5B) did not change significantly along the cell cycle progression. As observed for E2F1 (Fig. 5C, left panel; supplemental Fig. S5A), clAP1 was mainly recruited on the *CCNE* promoter in early S

phase (Fig. 5D, left panel; supplemental Fig. S5A). Both clAP1 and E2F1 were also recruited onto the *CCNE* promoter in late S phase (Fig. 5, C and D, left panels; supplemental Fig. S5A). The recruitment of E2F1 and clAP1 onto the *CCNA* promoter was also cell cycle-regulated and occurred later in S phase (Fig. 5, C and D, right panels; supplemental Fig. S5A). clAP1 and E2F1 were observed to bind the *CCNA* promoter in primary human



**FIGURE 3. Specific activity of cIAP1 on E2F1.** Gene luciferase experiments performed in HeLa cells transfected with a synthetic promoter containing 5xE2F binding sites (*p(5xE2F BS)*) (A, C) or CCNE promoter-luciferase reporter plasmid (*p(CCNE)*) (B) along with E2F1 (A–C), E2F2 or E2F3a constructs (C), and/or 500 ng of empty vector or cIAP1 (A–C), cIAP2- or XIAP (A, B)-encoding constructs. Luciferase activity was normalized to  $\beta$ -galactosidase activity and expressed as fold induction of promoter stimulated by empty vector alone. Mean  $\pm$  S.D. of one representative experiment is shown. The expression of indicated constructs was checked by immunoblot analysis (lower panels). HSC70: loading control. One representative experiment is shown.


CD34<sup>+</sup> hematopoietic cells (Fig. 5E). In accordance with the previously described exclusion of cIAP1 from the nucleus in cells undergoing differentiation (25), this recruitment is decreased when CD34<sup>+</sup> cells were induced to differentiate into CD14<sup>+</sup> monocytes upon M-CSF exposure (Fig. 5E).

*cIAP1 Is Required for E2F1 Binding to the CCNE Promoter*—Silencing of cIAP1 in HeLa cells using siRNA (Fig. 6, A–D) inhibited the capacity of E2F1 to stimulate the transcriptional expression of CCNE (Fig. 6A, left panel), and completely abolished the recruitment of cIAP1 and E2F1 on the CCNE promoter (Fig. 6, C and D, left panel). Interestingly, silencing of E2F1 (Fig. 6B) also inhibited the recruitment of cIAP1 (Fig. 6D, right panel). We confirmed these results in the CaSki human epidermoid cervical carcinoma cell line expressing the amplicon 11q21, which contains the *birc2* gene (16). As expected, we observed a very high expression of cIAP1 in both nucleus and cytoplasm-enriched fraction compared with HeLa cells (Fig.

6E). cIAP1 was also recruited on the cyclin E promoter, and silencing of cIAP1 prevented the recruitment of E2F1 on the CCNE promoter (Fig. 6F, supplemental Fig. S5B). Moreover, cIAP1 siRNA decreased the acetylation of histone H3 on the CCNE promoter that accompanied the transcriptional activation and increased the dimethylation of histone H3 on lysine 9 (H3K9), which is a feature of transcriptional repression (Fig. 6G) (40).

*cIAP1 Modulates Cyclin Expression and Cell Proliferation*—We analyzed the influence of cIAP1 on cyclin expression. siRNA-mediated down-regulation of cIAP1 decreased cyclin E and A mRNA (Fig. 7, A and B) and protein (Fig. 7C) expression in HeLa cells (Fig. 7, A–C) and in primary human mammary epithelial cells (Fig. 7C). A similar effect was observed by down-regulating cIAP1 with an antisense (AS) oligonucleotide construct in THP1 cells (Fig. 7C). Silencing of cIAP1 also decreased the cyclin E transcript in CaSki, B16F10

## cIAP1 Is a Transcriptional Co-regulator of E2F1




**FIGURE 4. cIAP1 is recruited on E2F binding site of CCN promoters.** Chromatin immunoprecipitation experiments performed using an anti-E2F1 (A, B, E), anti-cIAP1 (A, C–E), or an irrelevant antibody (Ig) in HeLa (A–E), U-2 OS, HT-29, THP1, HMEC (C), and CD34<sup>+</sup> primary myeloid cells (D). The genomic DNA region encompassing one E2F binding site of the CCNE (p(CCNE)) (B, C, E), CCNA (p(CCNA)) promoters (D) or a control sequence localized in CCNE gene (B, C left panels) were amplified by PCR (A) or qPCR (B–E). E, ChIP and re-ChIP experiments performed on HeLa cells. The sample was first immunoprecipitated with E2F1 or irrelevant antibody (Ig). The protein-DNA complex was eluted, and a second ChIP was performed using cIAP1 or irrelevant Ab. Results were normalized to input and expressed as relative recruitment compared with irrelevant antibody. Mean  $\pm$  S.D. of one representative experiment.

mouse melanoma and in L929 mouse fibroblast cell lines (Fig. 7D). We did not detect such an effect in murine embryonic fibroblast (MEF) (Fig. 7D), and MEF from deleted mice (MEF cIAP1<sup>-/-</sup>) did not show a decrease in the cyclin E transcript and protein when compared with wild-type MEF (supplemental Fig. S6, A and B). The cell fractionation experiment revealed that, in contrast to HeLa (Fig. 1A), HMEC (Fig. 7E), CaSki (Fig. 6E), B16F10, and L929 cell lines (Fig. 7E) in which cIAP1 is detected in the nuclear-enriched fraction, the expression of cIAP1 is almost restricted to the cytoplasm compartment in MEF (Fig. 7E), especially in the G<sub>0</sub>/G<sub>1</sub> and S

phase of the cell cycle, when E2F1 activity is maximal (supplemental Fig. S6C). Transfection of MEF cIAP1<sup>-/-</sup> with a cIAP1 construct induced cIAP1 expression in both nuclear and cytoplasm compartments (Fig. 7F) and enhanced E2F1 activity (supplemental Fig. S6D) and cyclin E expression (Fig. 7G). The analysis of cell proliferation and cell cycle repartition showed that down-regulation of cIAP1 (Fig. 7C) slowed down the cell proliferation (Fig. 8, A and B), decreased S phase of cell cycle (Fig. 8C) and increased G<sub>0</sub>/G<sub>1</sub> (Fig. 8, C and D) in HeLa (Fig. 7C and Fig. 8, A, C, D) and THP1 (Fig. 7C and Fig. 8, B and D) cells. We did not detect any sign of





**FIGURE 5. The recruitment of cIAP1 on CCN promoters is cell cycle-regulated.** A–D, HeLa cells were synchronized into early S phase by a thymidine double block and analyzed 0, 2, 4, 8, and 10 h after block release (see also supplemental Figs. S4 and S5). A, immunoblot analysis of cIAP1, cyclin E and B and E2F1. HSC70: loading control. B, endogenous E2F1 was immunoprecipitated with anti-E2F1 or irrelevant rabbit Ig (IgG) before immunoblot analysis of cIAP1 and E2F1. C and D, ChIP experiments of E2F1 (C) or cIAP1 (D) on *CCNE* ( $p(CCNE)$ ) (C and D left panels) or *CCNA* ( $p(CCNA)$ ) (C and D, right panels) promoter. E, ChIP of E2F1 and cIAP1 on *CCNA* promoter performed in undifferentiated (CD34<sup>+</sup>) and M-CSF-differentiated (CD34<sup>-</sup>/CD14<sup>+</sup>) myeloid cells. The genomic DNA region encompassing the E2F-binding site of *CCNE* or *CCNA* promoter was amplified by qPCR. Results were normalized to input and expressed as relative recruitment to irrelevant antibody (dotted line). Mean  $\pm$  S.D. of one representative experiment.

apoptosis (not shown), and the pan-caspase inhibitor z-VAD-fmk did not affect the capacity of cIAP1-siRNA to decrease HeLa cell growth rate (Fig. 8A). Moreover, the effect of cIAP1-siRNA on cell proliferation could be reverted by co-expression of the cIAP1-encoding vector (Fig. 8A). Silencing of cIAP1 (Fig. 7C) also decreased the proliferation rate as evaluated by 24 h EdU incorporation in primary HMEC (Fig. 8E). Moreover, expression of cIAP1 in the nuclear compartment of MEF cIAP1<sup>-/-</sup> (Fig. 7F) stimulated cell proliferation (Fig. 8F).


## DISCUSSION

In contrast to its closest homologs cIAP2 and XIAP that are localized in the cytoplasm, cIAP1 is expressed in the nucleus of a majority of normal cells until terminal differentiation (25, 27, 29) and in the nucleus of many cancer cells (15, 16, 25–28, 30). The present report identifies a nuclear function for cIAP1. The protein appears to be a co-regulator of E2F1-dependent transcriptional activity.

The E2F family of transcription factors includes 8 members subdivided into subgroups based on structural and

functional homologies. These transcription factors are potent cell cycle regulators through their capacity to regulate the expression of genes involved in G1-S phase transition, including *CCNE* and *CCNA* genes. E2F proteins promote either activation or repression of gene transcription, depending on the target gene, the pattern of co-regulator partners, and the cellular context (34, 41–43). Molecular partners affect E2F1 transcriptional activity *e.g.* Rb interaction with E2F1 is associated with transcription inhibition (44, 45). We show that cIAP1 binds a protein sequence of E2F1 (amino-acids 89–191) that overlaps with its DNA binding domain and favors E2F1-mediated transcriptional activation of *CCNE* and *CCNA* genes. cIAP1 appears to be important for optimal E2F1 mediated-cyclin E expression. Silencing of cIAP1 inhibits the recruitment of E2F1 on *CCNE* promoter, suggesting that cIAP1 is required for DNA binding of E2F1. Another molecular partner of E2F whose heterodimerization promotes the transcription factor binding to gene promoters is the co-activator DP1 (32, 46). We did not detect an interaction of cIAP1 with DP1 and DP1 did not

## *clAP1 Is a Transcriptional Co-regulator of E2F1*




**FIGURE 6. Contribution of clAP1 in the transcriptional activity of E2F1.** *A*, quantitative RT-PCR analysis of *ccne* (right panel), *e2f1* (medium panel), and *birc2* (left panel) mRNAs in HeLa cells transfected with empty or E2F1-encoding vector and control (Co) or clAP1-targeted siRNA. Results were normalized to cyclophilin mRNA and expressed relative to empty vector. Mean  $\pm$  S.D. of one representative experiment. Statistically significant differences (\*,  $p < 0.05$ ,  $n = 3$ , Student's  $t$  test). *B*, efficacy of clAP1 or E2F1-targeted siRNAs was checked by an immunoblot analysis. *HSC70*: loading control. *C*, *D* and *F*, *G*, chromatin immunoprecipitation experiments performed using an anti-E2F1 or an anti-clAP1 (C, D, F), an anti-acetyl histone H3 (Ac H3) or an anti-dimethyl histone H3 on lysine 9 (diMe H3K9) (G) or an irrelevant antibody (Ig) in HeLa (C, D, G) or CaSki (F) cells. The genomic DNA region encompassing the E2F-binding site of the *CCNE* promoter was amplified by PCR (C) or qPCR (D, F, G). Results are normalized to input and expressed as relative recruitment compared with irrelevant antibody. Mean  $\pm$  S.D. of one representative experiment (D, F, G) is shown. *MW*: molecular weight. The efficacy of clAP1-targeted siRNAs was checked by an immunoblot analysis (F, upper panel). *HSC70*: loading control. *E*, immunoblot analysis of clAP1, XIAP, E2F1, cyclin E, and cyclin A in the cytoplasm (C)- and nucleus (N)-enriched fractions of HeLa and CaSki cells. *HSC70*: loading control.

affect the capacity of clAP1 to stimulate E2F1 (not shown). clAP1 can directly interact with E2F1 in all stage of cell cycle. However, the recruitment of clAP1 on the cyclin gene promoter is cell cycle-regulated, peaking when the E2F1 activity is maximal. Additional partners or protein modifications may be required for the binding of this heterodimer to DNA at specific phases of the cell cycle.

clAP1 acts in collaboration with the TRAF2 protein to regulate the TNFR signaling pathway. TRAF2 is also observed to be

associated with clAP1 in the nuclear compartment (supplemental Fig. S1D). However, mutation within the BIR1 domain of clAP1 that abolishes its binding to TRAF2 does not interfere with the capacity of clAP1 to interact and stimulate E2F1, suggesting that the transcriptional regulation activity of clAP1 is independent of TRAF2. Most of the clAP1 functions identified so far involve its E3 ubiquitin ligase activity (1, 3, 47, 48). The ability of clAP1 to promote E2F1 transcriptional activity could have been related to the ubiquitination of E2F1 or other E2F1




**FIGURE 7. Down-regulation of clAP1 modulates cyclin expression.** clAP1 was down-regulated in HeLa (A–C), HMEC (C) CaSki, B16F10, L929 cells or MEF (D) by using siRNA (A–D) or in THP1 by transfecting an clAP1 antisense (AS) encoding construct (C). A, RT-PCR analysis of indicated mRNAs.  $\beta$ -2 microglobulin ( $\beta$ -2m) was used as control. B, RT-qPCR analysis of *ccne* (E) and *ccna* (A) mRNAs. Results are normalized to cyclophilin mRNA. Statistically significant differences (\*\*\*,  $p < 0.005$ ,  $n = 5$ , Student's *t* test). C, immunoblot analysis of indicated proteins in HeLa and HMEC cells transfected with clAP1 siRNA or in THP1 transfected with an clAP1 antisense (AS) encoding construct. HSC70: loading control. D, upper panels, RT-qPCR analysis of *ccne* mRNA in indicated cell lines. Results are normalized to cyclophilin mRNA. Lower panels, immunoblot analysis of clAP1. HSC70: loading control. E, immunoblot analysis of clAP1, XIAP, and E2F1 in the cytoplasm (C)- and nucleus (N)-enriched fractions of indicated cell lines. HSC70: loading control. F, immunoblot analysis of clAP1, XIAP, and E2F1 in the cytoplasm (C)- and nucleus (N)-enriched fractions of MEF clAP1<sup>-/-</sup> transfected with clAP1 construct. HSC70: loading control. G, RT-qPCR analysis of *ccne* and *birc2* mRNA in MEF transfected with the clAP1 construct. Results are normalized to cyclophilin mRNA.

molecular partners. Actually, we did not detect a ubiquitination of E2F1 by clAP1 (not shown), and a mutation that suppressed this E3 ligase activity did not abolish the ability of clAP1 to stimulate the E2F1 transcriptional activity in a luciferase gene reporter assay.

MEFs from animals in which the studied gene has been deleted is a useful tool to check the function of a studied protein. Unfortunately, these cells could not be used to explore the ability of clAP1 to promote E2F1 transcriptional activation as clAP1 is localized in the cytoplasm of these differentiated cells (supplemental Fig. S5), in accord with our previous observation that clAP1 migrates from the nucleus to the cytoplasm in cells undergoing terminal differentiation (25, 26). We show that nuclear clAP1 is recruited on the *CCNA* gene promoter in

undifferentiated hematopoietic stem cells and cannot be detected on this promoter in monocytes obtained by M-CSF-induced differentiation of these cells. Redistribution of clAP1 from the nucleus to the cytoplasm could favor the decrease in cell proliferation and cell cycle exit that characterizes terminal cell differentiation. Additional studies will indicate whether this redistribution of clAP1 could also favor the repression, inhibition, or degradation of E2F1 that is required for normal occurrence of differentiation in several cellular models (44, 49, 50).

The influence of clAP1 on tumor development has been well demonstrated in several mouse carcinoma models (18, 23, 24). Down-regulation of clAP1 decreases tumor cell growth *in vivo* (18, 23, 24) and decreases the proliferation in human breast



**FIGURE 8. Down-regulation of cIAP1 modulates cell proliferation and cell cycle repartition.** *A*, flow cytometry analysis of cell proliferation in HeLa cells transfected with control (si-Co) or cIAP1 (si-cIAP1) siRNA and cIAP1-encoding construct in the presence or not of zVAD-fmk 10  $\mu$ M. Results: mean  $\pm$  S.D. of at least three independent experiments. Statistically significant differences (\*\*,  $p < 0.001$ ,  $n = 5$ , Student's *t* test). *B*, cell proliferation was assessed by cell counting in THP1 clone transfected with empty or cIAP1 antisense (AS)-encoding construct as in Fig. 7C. Results are expressed as mean  $\pm$  S.D. of at least three independent experiments. *C* and *D*, cell cycle analysis in HeLa cell transfected with Co or cIAP1-siRNA. The cell cycle is evaluated in by flow cytometry after BrdU and PI staining of cells. *D*, percentage of cell in G<sub>0</sub>/G<sub>1</sub> phase of the cell cycle as analyzed by flow cytometry in HeLa cells transfected with control (Co) or cIAP1 siRNA or in THP1 cells transfected with empty vector (V) or an cIAP1 antisense encoding vector (AS). Mean  $\pm$  S.D. of at least three independent experiments is shown. Statistically significant differences (\*,  $p < 0.05$ ,  $n = 3$ , Student's *t* test). *E*, flow cytometry analysis of EdU incorporation in HMEC cells transfected with control (si-Co) or cIAP1 (si-cIAP1) siRNA as in Fig. 7C. One representative experiment was shown. *F*, flow cytometry analysis of EdU incorporation in MEF cIAP1<sup>-/-</sup> transfected with cIAP1 encoding construct as in Fig. 7F. One representative experiment is shown.

cancer cell line MCF-7 (51) and mouse primary carcinoma cells (24). Accordingly, we also observe a decrease in cell proliferation after cIAP1 down-regulation, which is accompanied by a

decrease in cyclin E and A expression. Interestingly, the murine hepatocellular carcinoma harboring 9qA1 amplicon, which contains *cIAP1*-, *cIAP2*-, and *yap1*-encoding genes were

observed to overexpress cyclin E (18). Moreover, a recent report showed that the 9A1 amplicon could be substituted by an inactivation of the E2F-repressor Rb in p53<sup>-/-</sup> mouse mammary carcinogenesis (24). The ability of cIAP1 to promote E2F1-mediated transcription activity of *CCN* genes, whose overexpression was associated with poor prognosis in several tumor types (52), could account for the oncogenic properties of the protein.

*Acknowledgments*—We thank Dr. D. Cress, Dr. B. Henglein, Dr. K. Katula, Dr. G. Leone, Dr. J. Lees, Dr. P. Meier, Dr. R. Pestell, Dr. J. Silke, Dr. R. Weinberg, and Dr. K.M. Yao for kindly providing plasmids and the cell line, Dr. N. Droin for efficient help in real-time PCR analysis, Shweta Tyagi for advice with the ChIP experiment, and Lydie Desoche for technical assistance. We are grateful for the use of the cytometry platform (IFR100, Dijon, France). We are grateful to Pascal Meier for critical reading of the manuscript.

**REFERENCES**

1. Dubrez-Daloz, L., Dupoux, A., and Cartier, J. (2008) *Cell Cycle* **7**, 1036–1046
2. Gyrd-Hansen, M., and Meier, P. (2010) *Nat. Rev. Cancer* **10**, 561–574
3. Varfolomeev, E., and Vucic, D. (2008) *Cell Cycle* **7**, 1511–1521
4. Varfolomeev, E., Blankenship, J. W., Wayson, S. M., Fedorova, A. V., Kaya-gaki, N., Garg, P., Zobel, K., Dynek, J. N., Elliott, L. O., Wallweber, H. J., Flygare, J. A., Fairbrother, W. J., Deshayes, K., Dixit, V. M., and Vucic, D. (2007) *Cell* **131**, 669–681
5. Vince, J. E., Wong, W. W., Khan, N., Feltham, R., Chau, D., Ahmed, A. U., Benetatos, C. A., Chunduru, S. K., Condon, S. M., McKinlay, M., Brink, R., Leverkus, M., Tergaonkar, V., Schneider, P., Callus, B. A., Koentgen, F., Vaux, D. L., and Silke, J. (2007) *Cell* **131**, 682–693
6. Dupoux, A., Cartier, J., Cathelin, S., Filomenko, R., Solary, E., and Dubrez-Daloz, L. (2009) *Blood* **113**, 175–185
7. Li, X., Yang, Y., and Ashwell, J. D. (2002) *Nature* **416**, 345–347
8. Vince, J. E., Chau, D., Callus, B., Wong, W. W., Hawkins, C. J., Schneider, P., McKinlay, M., Benetatos, C. A., Condon, S. M., Chunduru, S. K., Yeoh, G., Brink, R., Vaux, D. L., and Silke, J. (2008) *J. Cell Biol.* **182**, 171–184
9. Zarnegar, B. J., Wang, Y., Mahoney, D. J., Dempsey, P. W., Cheung, H. H., He, J., Shiba, T., Yang, X., Yeh, W. C., Mak, T. W., Korneluk, R. G., and Cheng, G. (2008) *Nat. Immunol.* **9**, 1371–1378
10. Zhao, Y., Conze, D. B., Hanover, J. A., and Ashwell, J. D. (2007) *J. Biol. Chem.* **282**, 7777–7782
11. Tang, E. D., Wang, C. Y., Xiong, Y., and Guan, K. L. (2003) *J. Biol. Chem.* **278**, 37297–37305
12. Bertrand, M. J., Milutinovic, S., Dickson, K. M., Ho, W. C., Boudreaux, A., Durkin, J., Gillard, J. W., Jaquith, J. B., Morris, S. J., and Barker, P. A. (2008) *Mol. Cell* **30**, 689–700
13. Park, S. M., Yoon, J. B., and Lee, T. H. (2004) *FEBS Lett.* **566**, 151–156
14. Snijders, A. M., Schmidt, B. L., Fridlyand, J., Dekker, N., Pinkel, D., Jordan, R. C., and Albertson, D. G. (2005) *Oncogene* **24**, 4232–4242
15. Imoto, I., Yang, Z. Q., Pimkhaokham, A., Tsuda, H., Shimada, Y., Imamura, M., Ohki, M., and Inazawa, J. (2001) *Cancer Res.* **61**, 6629–6634
16. Imoto, I., Tsuda, H., Hirasawa, A., Miura, M., Sakamoto, M., Hirohashi, S., and Inazawa, J. (2002) *Cancer Res.* **62**, 4860–4866
17. Dai, Z., Zhu, W. G., Morrison, C. D., Brena, R. M., Smiraglia, D. J., Raval, A., Wu, Y. Z., Rush, L. J., Ross, P., Molina, J. R., Otterson, G. A., and Plass, C. (2003) *Hum. Mol. Genet.* **12**, 791–801
18. Zender, L., Spector, M. S., Xue, W., Flemming, P., Cordon-Cardo, C., Silke, J., Fan, S. T., Luk, J. M., Wigler, M., Hannon, G. J., Mu, D., Lucito, R., Powers, S., and Lowe, S. W. (2006) *Cell* **125**, 1253–1267
19. Gordon, G. J., Mani, M., Mukhopadhyay, L., Dong, L., Yeap, B. Y., Sugarbaker, D. J., and Bueno, R. (2007) *J. Pathol.* **211**, 439–446
20. Tamm, I., Kornblau, S. M., Segall, H., Krajewski, S., Welsh, K., Kitada, S.,

- Scudiero, D. A., Tudor, G., Qui, Y. H., Monks, A., Andreeff, M., and Reed, J. C. (2000) *Clin. Cancer Res.* **6**, 1796–1803
21. Kempkensteffen, C., Hinz, S., Christoph, F., Köllermann, J., Krause, H., Schrader, M., Schostak, M., Miller, K., and Weikert, S. (2007) *Int. J. Cancer* **120**, 1081–1086
22. Krajewska, M., Krajewski, S., Banares, S., Huang, X., Turner, B., Bubendorf, L., Kallioniemi, O. P., Shabaik, A., Vitiello, A., Peehl, D., Gao, G. J., and Reed, J. C. (2003) *Clin. Cancer Res.* **9**, 4914–4925
23. Ma, O., Cai, W. W., Zender, L., Dayaram, T., Shen, J., Herron, A. J., Lowe, S. W., Man, T. K., Lau, C. C., and Donehower, L. A. (2009) *Cancer Res.* **69**, 2559–2567
24. Cheng, L., Zhou, Z., Flesken-Nikitin, A., Toshkov, I. A., Wang, W., Camps, J., Ried, T., and Nikitin, A. Y. (2010) *Oncogene* **38**, 62–71
25. Plenchette, S., Cathelin, S., Rébé, C., Launay, S., Ladoire, S., Sordet, O., Ponnelle, T., Debili, N., Phan, T. H., Padua, R. A., Dubrez-Daloz, L., and Solary, E. (2004) *Blood* **104**, 2035–2043
26. Didelot, C., Lanneau, D., Brunet, M., Bouchot, A., Cartier, J., Jacquel, A., Ducoroy, P., Cathelin, S., Decolonne, N., Chiosis, G., Dubrez-Daloz, L., Solary, E., and Garrido, C. (2008) *Cell Death Differ.* **15**, 859–866
27. Samuel, T., Okada, K., Hyer, M., Welsh, K., Zapata, J. M., and Reed, J. C. (2005) *Cancer Res.* **65**, 210–218
28. Ponnelle, T., Chapusot, C., Martin, L., Bonithon-Kopp, C., Bouvier, A. M., Plenchette, S., Rageot, D., Favre, J., Solary, E., and Piard, F. (2003) *Pathol. Res. Pract.* **199**, 723–731
29. Vischioni, B., van der Valk, P., Span, S. W., Kruyt, F. A., Rodriguez, J. A., and Giaccone, G. (2006) *Hum. Pathol.* **37**, 78–86
30. Tanimoto, T., Tsuda, H., Imazeki, N., Ohno, Y., Imoto, I., Inazawa, J., and Matsubara, O. (2005) *Cancer Lett.* **224**, 141–151
31. DeGregori, J., and Johnson, D. G. (2006) *Curr. Mol. Med.* **6**, 739–748
32. Dimova, D. K., and Dyson, N. J. (2005) *Oncogene* **24**, 2810–2826
33. Blais, A., and Dynlacht, B. D. (2007) *Curr. Opin. Cell Biol.* **19**, 658–662
34. Tyagi, S., Chabes, A. L., Wysocka, J., and Herr, W. (2007) *Mol. Cell* **27**, 107–119
35. Sun, A., Bagella, L., Tutton, S., Romano, G., and Giordano, A. (2007) *J. Cell Biochem.* **102**, 1400–1404
36. Paggetti, J., Largeot, A., Aucagne, R., Jacquel, A., Lagrange, B., Yang, X. J., Solary, E., Bastie, J. N., and Delva, L. (2010) *Oncogene* **29**, 5019–5031
37. Mace, P. D., Smits, C., Vaux, D. L., Silke, J., and Day, C. L. (2010) *J. Mol. Biol.* **400**, 8–15
38. Geng, Y., Eaton, E. N., Picón, M., Roberts, J. M., Lundberg, A. S., Gifford, A., Sardet, C., and Weinberg, R. A. (1996) *Oncogene* **12**, 1173–1180
39. Conze, D. B., Albert, L., Ferrick, D. A., Goeddel, D. V., Yeh, W. C., Mak, T., and Ashwell, J. D. (2005) *Mol. Cell Biol.* **25**, 3348–3356
40. Kouzarides, T. (2007) *Cell* **128**, 693–705
41. Wang, C., Chen, L., Hou, X., Li, Z., Kabra, N., Ma, Y., Nemoto, S., Finkel, T., Gu, W., Cress, W. D., and Chen, J. (2006) *Nat. Cell Biol.* **8**, 1025–1031
42. Ianari, A., Gallo, R., Palma, M., Alesse, E., and Gulino, A. (2004) *J. Biol. Chem.* **279**, 30830–30835
43. Hallstrom, T. C., and Nevins, J. R. (2006) *Genes Dev.* **20**, 613–623
44. Chong, J. L., Wenzel, P. L., Sáenz-Robles, M. T., Nair, V., Ferrey, A., Hagan, J. P., Gomez, Y. M., Sharma, N., Chen, H. Z., Ouseph, M., Wang, S. H., Trikha, P., Culp, B., Mezache, L., Winton, D. J., Sansom, O. J., Chen, D., Bremner, R., Cantalupo, P. G., Robinson, M. L., Pipas, J. M., and Leone, G. (2009) *Nature* **462**, 930–934
45. Sahin, F., and Sladek, T. L. (2010) *Int. J. Biol. Sci.* **6**, 116–128
46. Polager, S., and Ginsberg, D. (2008) *Trends Cell Biol.* **18**, 528–535
47. LaCasse, E. C., Mahoney, D. J., Cheung, H. H., Plenchette, S., Baird, S., and Korneluk, R. G. (2008) *Oncogene* **27**, 6252–6275
48. Srinivasula, S. M., and Ashwell, J. D. (2008) *Mol. Cell* **30**, 123–135
49. Gibbs, J. D., Liebermann, D. A., and Hoffman, B. (2008) *Oncogene* **27**, 98–106
50. Ivanova, I. A., Nakrieko, K. A., and Dagnino, L. (2009) *Oncogene* **28**, 52–62
51. Xu, L., Zhu, J., Hu, X., Zhu, H., Kim, H. T., LaBaer, J., Goldberg, A., and Yuan, J. (2007) *Mol. Cell* **28**, 914–922
52. Sutherland, R. L., and Musgrove, E. A. (2004) *J. Mammary Gland Biol. Neoplasia* **9**, 95–104

**Cellular Inhibitor of Apoptosis Protein-1 (cIAP1) Can Regulate E2F1  
Transcription Factor-mediated Control of Cyclin Transcription**

Jessy Cartier, Jean Berthelet, Arthur Marivin, Simon Gemble, Valérie Edmond,  
Stéphanie Plenchette, Brice Lagrange, Arlette Hammann, Alban Dupoux, Laurent  
Delva, Béatrice Eymin, Eric Solary and Laurence Dubrez

*J. Biol. Chem.* 2011, 286:26406-26417.

doi: 10.1074/jbc.M110.191239 originally published online June 8, 2011

---

Access the most updated version of this article at doi: [10.1074/jbc.M110.191239](https://doi.org/10.1074/jbc.M110.191239)

Alerts:

- [When this article is cited](#)
- [When a correction for this article is posted](#)

[Click here](#) to choose from all of JBC's e-mail alerts

Supplemental material:

<http://www.jbc.org/content/suppl/2011/06/08/M110.191239.DC1>

This article cites 52 references, 14 of which can be accessed free at  
<http://www.jbc.org/content/286/30/26406.full.html#ref-list-1>